Hemp-derived CBD giant Charlotte’s Web Holdings is positioning itself to enter THC and marijuana markets. The Boulder, Colorado, company says it has signed a five-year, $8 million purchase agreement option with a marijuana company started by its founders, Stanley Brothers USA Holdings Inc. The deal allows Charlotte’s Web to take over the marijuana business after
Charlotte’s Web Holdings
(This opinion column appears in the February issue of Marijuana Business Magazine.) Everyone in the hemp industry knows the story of Charlotte’s Web: A group of well-meaning brothers working under Colorado’s medical marijuana system developed a cannabis strain that worked miracles on a sick little girl named Charlotte. Word spread about the awe-inspiring results of
(Editor’s note: This story is part of a recurring series of commentaries from professionals connected to the hemp industry. Julie Lerner is CEO of PanXchange, a commodity trading platform and benchmark price provider.) Basing the multibillion-dollar, pie-in-the-sky forecasts for the U.S. addressable market for CBD on retail shelf prices disturbs me. It’s as illogical as
Charlotte’s Web Holdings Inc. lost $6.6 million last quarter as expenses outstripped rising revenue and the pandemic continued to cool sales. The CBD giant based in Boulder, Colorado, reported revenue of $25.2 million for the quarter that ended Sept. 30, up 0.4% from the same period a year ago. The company said in its third-quarter
CBD products in the U.S. have gotten cheaper over the last year, driven by falling prices for hemp biomass, reduced production expenses, and plans to reach consumers with less disposable income as unemployment numbers soar amid COVID-19. The aggregate price of hemp CBD biomass dropped by 79% from April 2019 to April 2020, according to
A third-party consumer research study looking at CBD’s effects on humans, meant to help gather liver safety data that the U.S. Food and Drug Administration needs to move forward with regulation, is set to begin in July. The protocol for the study, sponsored and led by ValidCare, a Colorado-based firm that conducts clinical and market
A third-party consumer research study looking at CBD’s effects on humans, meant to help gather liver safety data that the U.S. Food and Drug Administration needs to move forward with regulation, is set to begin in July. The protocol for the study, sponsored and led by ValidCare, a Colorado-based firm that conducts clinical and market
Charlotte Figi, the namesake of a Colorado CBD company who became a symbol for the therapeutic potential of cannabidiol and medical cannabis, has reportedly died from complications associated with COVID-19, the illness caused by the coronavirus pandemic. Charlotte’s death was announced late Tuesday in a Facebook post by a family friend. No time or location